Results 201 to 210 of about 860,910 (266)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

A theoretical approach to the remediation of saline streamflow conditions downstream of the Nwanedi catchment reservoir. [PDF]

Sci Rep
Gumbo AD, Kapangaziwiri E, Mugari E, Kativhu S, Manjoro M, Maswanganye SE, Machimana L, Nethengwe N.   +7 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Commentary on "Protecting Against Unintended Risk From Student Quality Improvement Projects in Health Care". [PDF]

Adv Health Inf Sci Pract
Watzlaf VJM.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Leveraging technologies for data management and sharing to foster collaboration and implement data spaces. [PDF]

Data Brief
Chrysakis I, Antzoulatos G, Sánchez L, Parreira JX, Skoutas D, Jayawardene I, Bernardo RD, Vargiu E, Vrochidis S, Mannens E.   +9 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Development and Usability of a Dashboard for Quality Monitoring and Resident-Centered Care in Australian Residential Long-Term Care: Mixed-Methods Study. [PDF]

JMIR Hum Factors
Dendere R, Stockwell-Smith G, Lang M, Hargrave M, Mayfield S, Gray LC.   +5 more
europepmc   +1 more source

Tiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity. [PDF]

PLOS Glob Public Health
Rusatira JC, Pal E, Uwimana JB, Khan A, Novoa MD, Suryanarayanan S, Schoukroun-Barnes L, Peterson C, Michtalik H, Kapeta AB, Mukanga D, Ahmed S, Lumpkin M, Preston C.   +13 more
europepmc   +1 more source